Related Experiment Video
Updated: Jun 3, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Antenatal steroid administration for premature neonates in California
Henry C Lee1, Audrey Lyndon, Yair J Blumenfeld
1From the Department of Pediatrics, Department of Family Health Care Nursing, and Departments of Medicine and Health Policy, University of California, San Francisco, San Francisco, California; California Perinatal Quality Care Collaborative, Palo Alto, California; and the Departments of Obstetrics and Gynecology and Pediatrics, Stanford University, Stanford, California.
Insights
Many premature infants miss antenatal steroid doses, particularly those from disadvantaged backgrounds. Quality improvement initiatives are crucial to ensure all eligible mothers receive these life-saving treatments.
Area of Science:
- Perinatal medicine
- Neonatal care
- Public health
Background:
- Antenatal steroids are crucial for fetal lung maturation in premature infants.
- Quality improvement initiatives aim to increase antenatal steroid administration rates.
- Sustained improvements require understanding persistent barriers and risk factors.
Purpose of the Study:
- To identify risk factors for premature neonates not receiving antenatal steroids.
- To assess the long-term impact of a quality-improvement collaborative on antenatal steroid administration.
- To inform targeted interventions for improving antenatal steroid coverage.
Main Methods:
- Analysis of a population-based cohort of premature neonates (2005-2007) from the California Perinatal Quality Care Collaborative.
- Linking clinical and administrative data to identify sociodemographic and medical risk factors.
- Utilizing a random effects logistic regression model to determine independent risk factors.
Main Results:
- 23.1% of eligible premature neonates did not receive antenatal steroids.
- Hispanic mothers, younger mothers, and those without prenatal care were less likely to receive steroids.
- Hospitals with prior quality improvement collaborative participation had significantly higher administration rates (85% vs. 69%).
Conclusions:
- Significant disparities exist in antenatal steroid administration among eligible mothers.
- Targeted quality improvement initiatives are necessary to address specific high-risk groups.
- Sustained efforts are needed to ensure equitable access to antenatal steroids.
Objectives:
To estimate risk factors for premature neonates not receiving antenatal steroids in a population-based cohort and to determine whether the gains of a quality-improvement collaborative project on antenatal steroid administration were sustained long-term.
Methods:
Clinical data for premature neonates born in 2005–2007 were obtained from the California Perinatal Quality Care Collaborative, which collects data on more than 90% of neonatal admissions in California. Eligible neonates had a birth weight of less than 1,500 g or gestational age less than 34 weeks and were born at a Collaborative hospital. These data were linked to administrative data from California Vital Statistics. Sociodemographic and medical risk factors for not receiving antenatal steroids were determined. We also examined the effect of birth hospital participation in a previous quality-improvement collaborative project. A random effects logistic regression model was used to determine independent risk factors.
Results:
Of 15,343 eligible neonates, 23.1% did not receive antenatal steroids in 2005–2007. Hispanic mothers (25.6%), mothers younger than age 20 (27.6%), and those without prenatal care (52.2%) were less likely to receive antenatal steroids. Mothers giving birth vaginally (26.8%) and mothers with a diagnosis of fetal distress (26.5%) were also less likely to receive antenatal steroids. Rupture of membranes before delivery and multiple gestations were associated with higher likelihood of antenatal steroid administration. Hospitals that participated in a quality-improvement collaborative in 1999– 2000 had higher rates of antenatal steroid administration (85% compared with 69%, P<.001).
Conclusion:
A number of eligible mothers do not receive antenatal steroids. Quality-improvement initiatives to improve antenatal steroid administration could target specific high-risk groups.
Related Concept Videos
Drug Dosing: Infants and Children
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Teratogenicity
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Intrauterine Drug Delivery Systems
